CN102985425A - 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途 - Google Patents

作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途 Download PDF

Info

Publication number
CN102985425A
CN102985425A CN2011800339890A CN201180033989A CN102985425A CN 102985425 A CN102985425 A CN 102985425A CN 2011800339890 A CN2011800339890 A CN 2011800339890A CN 201180033989 A CN201180033989 A CN 201180033989A CN 102985425 A CN102985425 A CN 102985425A
Authority
CN
China
Prior art keywords
pyrimidine
pyrrolo
nonane
diaza spiro
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800339890A
Other languages
English (en)
Chinese (zh)
Inventor
S·F·尼尔森
D·R·格雷夫
G·格鲁-索伦森
C·里特斯嘉德
S·C·舒
A·G·萨姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CN102985425A publication Critical patent/CN102985425A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800339890A 2010-07-09 2011-07-08 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途 Pending CN102985425A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36309510P 2010-07-09 2010-07-09
US61/363,095 2010-07-09
PCT/DK2011/000080 WO2012003829A1 (en) 2010-07-09 2011-07-08 Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
CN102985425A true CN102985425A (zh) 2013-03-20

Family

ID=44513700

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800339890A Pending CN102985425A (zh) 2010-07-09 2011-07-08 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途

Country Status (7)

Country Link
US (1) US9586961B2 (enExample)
EP (1) EP2590981B1 (enExample)
JP (1) JP2013533868A (enExample)
CN (1) CN102985425A (enExample)
RU (1) RU2013105450A (enExample)
TW (1) TW201204732A (enExample)
WO (1) WO2012003829A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242321A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 苄基哌嗪类化合物及其抗肿瘤用途
CN103396414A (zh) * 2013-07-16 2013-11-20 浙江医药高等专科学校 咪唑取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN104072499A (zh) * 2013-03-29 2014-10-01 黄传满 哌嗪取代嘧啶类化合物及其用途
CN105712998A (zh) * 2014-12-05 2016-06-29 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
CN106061973A (zh) * 2013-12-05 2016-10-26 辉瑞公司 吡咯并[2,3‑d]嘧啶基、吡咯并[2,3‑b]吡嗪基和吡咯并[2,3‑d]吡啶基丙烯酰胺
CN108069986A (zh) * 2017-12-08 2018-05-25 牡丹江医学院 一种治疗角膜炎的活性药物及其制备方法
CN109689663A (zh) * 2016-09-14 2019-04-26 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101214A1 (es) * 2014-07-22 2016-11-30 Bayer Cropscience Ag Ciano-cicloalquilpenta-2,4-dienos, ciano-cicloalquilpent-2-en-4-inas, ciano-heterociclilpenta-2,4-dienos y ciano-heterociclilpent-2-en-4-inas sustituidos como principios activos contra el estrés abiótico de plantas
US10851116B2 (en) * 2017-01-20 2020-12-01 Leo Pharma A/S Bicyclic amines as novel JAK kinase inhibitors
CN110248663A (zh) * 2017-02-03 2019-09-17 利奥制药有限公司 作为新型JAK激酶抑制剂的5-(7H-吡咯并[2,3-d]嘧啶-4-基)-5-氮杂螺[2.5]辛烷-8-甲酸衍生物
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
JP7528196B2 (ja) 2019-09-05 2024-08-05 インサイト・コーポレイション アトピー性皮膚炎のかゆみを軽減するためのルキソリチニブ製剤
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN118255773A (zh) 2019-12-19 2024-06-28 詹森药业有限公司 取代的直链螺环衍生物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065908A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
CN1305479A (zh) * 1998-06-19 2001-07-25 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
WO2009021169A2 (en) * 2007-08-08 2009-02-12 Lexicon Pharmaceuticals, Inc. (7h-pyrr0l0 [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation
CN101679440A (zh) * 2007-04-02 2010-03-24 帕劳制药股份有限公司 作为jak3抑制剂的吡咯并嘧啶衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
DK2049529T3 (da) 2006-07-14 2010-11-29 Merck Sharp & Dohme Substituerede diazepan-orexin-receptor- antagonister
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CN101981036B (zh) 2008-02-06 2013-09-04 诺瓦提斯公司 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065908A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
CN1305479A (zh) * 1998-06-19 2001-07-25 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
CN101679440A (zh) * 2007-04-02 2010-03-24 帕劳制药股份有限公司 作为jak3抑制剂的吡咯并嘧啶衍生物
WO2009021169A2 (en) * 2007-08-08 2009-02-12 Lexicon Pharmaceuticals, Inc. (7h-pyrr0l0 [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072499A (zh) * 2013-03-29 2014-10-01 黄传满 哌嗪取代嘧啶类化合物及其用途
CN103242321A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 苄基哌嗪类化合物及其抗肿瘤用途
CN103396414A (zh) * 2013-07-16 2013-11-20 浙江医药高等专科学校 咪唑取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103396414B (zh) * 2013-07-16 2015-06-03 浙江医药高等专科学校 咪唑取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN106061973A (zh) * 2013-12-05 2016-10-26 辉瑞公司 吡咯并[2,3‑d]嘧啶基、吡咯并[2,3‑b]吡嗪基和吡咯并[2,3‑d]吡啶基丙烯酰胺
CN107417684A (zh) * 2013-12-05 2017-12-01 辉瑞公司 杂环丙烯酰胺
CN106061973B (zh) * 2013-12-05 2019-07-09 辉瑞公司 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺
CN105712998A (zh) * 2014-12-05 2016-06-29 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
CN109689663A (zh) * 2016-09-14 2019-04-26 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN109689663B (zh) * 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN108069986A (zh) * 2017-12-08 2018-05-25 牡丹江医学院 一种治疗角膜炎的活性药物及其制备方法

Also Published As

Publication number Publication date
US9586961B2 (en) 2017-03-07
WO2012003829A1 (en) 2012-01-12
TW201204732A (en) 2012-02-01
RU2013105450A (ru) 2014-08-20
EP2590981B1 (en) 2014-09-03
EP2590981A1 (en) 2013-05-15
US20130172325A1 (en) 2013-07-04
JP2013533868A (ja) 2013-08-29

Similar Documents

Publication Publication Date Title
CN102985425A (zh) 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途
CN112312904B (zh) 螺环化合物
AU2016240033B2 (en) 1-cyano-pyrrolidine compounds as USP30 inhibitors
EP2451813B1 (en) Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
CN103476768B (zh) 6,5-杂环炔丙醇化合物及其用途
EP3324977B1 (en) Benzodiazepine derivatives as rsv inhibitors
CN1871240B (zh) 吡咯并嘧啶酮衍生物
EP3952870B1 (en) Phosphatidylinositol 3-kinase inhibitors
CN102281875B (zh) 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
CA2588761C (en) 2,4(4,6)pyrimidine derivatives
KR101171433B1 (ko) 이미다졸리딘온 유도체
CN108602776A (zh) 用作irak抑制剂的杂芳基化合物及其用途
EP2945623A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
NZ539193A (en) Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
HUE034807T2 (en) New quinoline-substituted compound
WO2020150545A1 (en) Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
EP3697410A1 (en) Benzimidazole derivatives and their uses
CN111032630B (zh) 一种化合物，其药物组合物及其用途及应用
RU2415853C2 (ru) Бензимидазолы, применимые в качестве ингибиторов протеинкиназ
CN112041319B (zh) 三唑、咪唑和吡咯稠合的哌嗪衍生物及其作为mGlu5受体的调节剂的应用
CN110272419A (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN105985354B (zh) 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
HK1181752A (en) Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
WO2026026970A1 (zh) 稠合环类化合物及其中间体和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1181752

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130320

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1181752

Country of ref document: HK